Drugs / GE-141
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03078192 | May 2017 → Oct 2020 | pulmonary artery disease | Bastiaan Driehuys | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GE-141 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03078192 ↗ |
| Known as | Hyperpolarized 129Xenon gas | “GE-141, Hyperpolarized 129Xenon gas” NCT03078192 ↗ |